• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SWI/SNF 复合物突变在肝细胞癌的发生发展中的作用及其对免疫系统的调控作用:综述。

The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review.

机构信息

Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Cell Prolif. 2020 Apr;53(4):e12791. doi: 10.1111/cpr.12791. Epub 2020 Mar 11.

DOI:10.1111/cpr.12791
PMID:32162380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7162795/
Abstract

Hepatocellular carcinoma (HCC) is a primary liver malignancy with a high global prevalence and a dismal prognosis. Studies are urgently needed to examine the molecular pathogenesis and biological characteristics of HCC. Chromatin remodelling, an integral component of the DNA damage response, protects against DNA damage-induced genome instability and tumorigenesis by triggering the signalling events that activate the interconnected DNA repair pathways. The SWI/SNF complexes are one of the most extensively investigated adenosine triphosphate-dependent chromatin remodelling complexes, and mutations in genes encoding SWI/SNF subunits are frequently observed in various human cancers, including HCC. The mutated SWI/SNF complex subunits exert dual functions by accelerating or inhibiting HCC initiation and progression. Furthermore, the abnormal SWI/SNF complexes influence the transcription of interferon-stimulated genes, as well as the differentiation, activation and recruitment of several immune cell types. In addition, they exhibit synergistic effects with immune checkpoint inhibitors in the treatment of diverse tumour types. Therefore, understanding the mutations and deficiencies of the SMI/SNF complexes, together with the associated functional mechanisms, may provide a novel strategy to treat HCC through targeting the related genes or modulating the tumour microenvironment.

摘要

肝细胞癌(HCC)是一种原发性肝脏恶性肿瘤,具有较高的全球发病率和较差的预后。目前迫切需要研究 HCC 的分子发病机制和生物学特征。染色质重塑是 DNA 损伤反应的一个组成部分,通过触发激活相互关联的 DNA 修复途径的信号事件,保护细胞免受 DNA 损伤诱导的基因组不稳定性和肿瘤发生。SWI/SNF 复合物是研究最广泛的腺苷三磷酸依赖性染色质重塑复合物之一,编码 SWI/SNF 亚基的基因突变在包括 HCC 在内的多种人类癌症中经常观察到。突变的 SWI/SNF 复合物亚基通过加速或抑制 HCC 的起始和进展发挥双重功能。此外,异常的 SWI/SNF 复合物会影响干扰素刺激基因的转录,以及多种免疫细胞类型的分化、激活和募集。此外,它们在治疗多种肿瘤类型的免疫检查点抑制剂中具有协同作用。因此,了解 SMI/SNF 复合物的突变和缺陷,以及相关的功能机制,可能为通过靶向相关基因或调节肿瘤微环境来治疗 HCC 提供一种新策略。

相似文献

1
The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review.SWI/SNF 复合物突变在肝细胞癌的发生发展中的作用及其对免疫系统的调控作用:综述。
Cell Prolif. 2020 Apr;53(4):e12791. doi: 10.1111/cpr.12791. Epub 2020 Mar 11.
2
Genetic variant in SWI/SNF complexes influences hepatocellular carcinoma risk: a new clue for the contribution of chromatin remodeling in carcinogenesis.SWI/SNF复合物中的基因变异影响肝细胞癌风险:染色质重塑在致癌过程中作用的新线索
Sci Rep. 2014 Feb 21;4:4147. doi: 10.1038/srep04147.
3
The SWI/SNF chromatin remodelling complex: Its role in maintaining genome stability and preventing tumourigenesis.SWI/SNF染色质重塑复合体:其在维持基因组稳定性和预防肿瘤发生中的作用。
DNA Repair (Amst). 2015 Aug;32:127-133. doi: 10.1016/j.dnarep.2015.04.023. Epub 2015 May 1.
4
Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.人类癌症中 SWI/SNF 染色质重塑基因的失活突变。
Jpn J Clin Oncol. 2013 Sep;43(9):849-55. doi: 10.1093/jjco/hyt101. Epub 2013 Jul 30.
5
mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.mTORC1 促进肝癌中 ARID1A 的降解和致癌性染色质重塑。
Cancer Res. 2021 Nov 15;81(22):5652-5665. doi: 10.1158/0008-5472.CAN-21-0206. Epub 2021 Aug 24.
6
ARID2 Chromatin Remodeler in Hepatocellular Carcinoma.ARID2 染色质重塑因子在肝细胞癌中的作用。
Cells. 2020 Sep 23;9(10):2152. doi: 10.3390/cells9102152.
7
SWI/SNF: Complex complexes in genome stability and cancer.SWI/SNF:基因组稳定性和癌症中的复杂复合物。
DNA Repair (Amst). 2019 May;77:87-95. doi: 10.1016/j.dnarep.2019.03.007. Epub 2019 Mar 15.
8
Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.肝细胞癌中 SWI/SNF 染色质重塑亚基-BRG1 和 BRM 的改变。
Liver Int. 2013 Jan;33(1):105-17. doi: 10.1111/liv.12005. Epub 2012 Oct 22.
9
The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma.SWI/SNF 染色质重塑复合物在胰腺导管腺癌中的作用。
Cancer Sci. 2021 Feb;112(2):490-497. doi: 10.1111/cas.14768. Epub 2020 Dec 28.
10
Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy.非小细胞肺癌中 SWI/SNF 染色质重塑因子的失调:对包括免疫疗法在内的癌症疗法的影响。
Biomolecules. 2023 Jun 13;13(6):984. doi: 10.3390/biom13060984.

引用本文的文献

1
Deciphering hypoxia's role in hepatocellular carcinoma prognosis with single-cell approaches.利用单细胞方法解读缺氧在肝细胞癌预后中的作用。
Discov Oncol. 2025 Jul 26;16(1):1411. doi: 10.1007/s12672-025-03201-y.
2
Oncogenic function of growth arrest-specific transcript 5 by competing with miR-423-3p to regulate SMARCA4 in hepatocellular carcinoma.生长停滞特异性转录本5通过与miR-423-3p竞争来调控肝细胞癌中的SMARCA4的致癌功能。
Exp Mol Med. 2025 Jun 2. doi: 10.1038/s12276-025-01459-4.
3
Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors.

本文引用的文献

1
Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.单区域样本评估肝细胞癌肿瘤免疫微环境的可靠性。
J Hepatol. 2020 Mar;72(3):489-497. doi: 10.1016/j.jhep.2019.09.032. Epub 2019 Oct 18.
2
Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.SWI/SNF 复合物表达缺失的非小细胞肺癌与侵袭性临床病理特征、PD-L1 阳性状态和高肿瘤突变负担相关。
Lung Cancer. 2019 Dec;138:35-42. doi: 10.1016/j.lungcan.2019.10.009. Epub 2019 Oct 13.
3
SWI/SNF复合物高频突变亚基在肿瘤中作用的研究进展
Front Oncol. 2024 Dec 4;14:1463892. doi: 10.3389/fonc.2024.1463892. eCollection 2024.
4
Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors.经导管动脉化疗栓塞术联合酪氨酸激酶抑制剂治疗肝细胞癌患者的生存预测模型的建立与验证。
Radiol Med. 2024 Nov;129(11):1597-1610. doi: 10.1007/s11547-024-01890-z. Epub 2024 Oct 14.
5
Actin like 6A is a prognostic biomarker and associated with immune cell infiltration in cancers.肌动蛋白样6A是一种预后生物标志物,与癌症中的免疫细胞浸润有关。
Discov Oncol. 2024 Sep 27;15(1):503. doi: 10.1007/s12672-024-01388-0.
6
Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy.肿瘤相关巨噬细胞(TAMs)的表观遗传调控:肝细胞癌(HCC)免疫治疗的一种潜在方法。
Expert Rev Mol Med. 2024 Sep 25;26:e18. doi: 10.1017/erm.2024.9.
7
Gene amplification of chromatin remodeling factor and low protein expression of ACTL6A are unfavorable factors in ovarian high‑grade serous carcinoma.染色质重塑因子的基因扩增和ACTL6A蛋白低表达是卵巢高级别浆液性癌的不利因素。
Oncol Lett. 2024 Mar 7;27(5):196. doi: 10.3892/ol.2024.14329. eCollection 2024 May.
8
SWI/SNF Chromatin Remodelers: Structural, Functional and Mechanistic Implications.SWI/SNF 染色质重塑因子:结构、功能与机制的影响。
Cell Biochem Biophys. 2023 Jun;81(2):167-187. doi: 10.1007/s12013-023-01140-5. Epub 2023 Apr 29.
9
Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.用于肝细胞癌治疗的免疫检查点和表观遗传调节剂的联合靶向治疗
Oncogene. 2023 Mar;42(14):1051-1057. doi: 10.1038/s41388-023-02646-1. Epub 2023 Mar 1.
10
Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.表观遗传学修饰相关机制导致肝癌对免疫检查点抑制的耐药性。
Front Immunol. 2023 Jan 4;13:1043667. doi: 10.3389/fimmu.2022.1043667. eCollection 2022.
Mitochondrial Dysfunction in the Transition from NASH to HCC.
非酒精性脂肪性肝炎(NASH)向肝细胞癌(HCC)转变过程中的线粒体功能障碍
Metabolites. 2019 Oct 16;9(10):233. doi: 10.3390/metabo9100233.
4
Liver graft rejection following immune checkpoint inhibitors treatment: a review.免疫检查点抑制剂治疗后肝移植物排斥反应:综述。
Med Oncol. 2019 Oct 11;36(11):94. doi: 10.1007/s12032-019-1316-7.
5
Chromatin remodelling factor BAF155 protects hepatitis B virus X protein (HBx) from ubiquitin-independent proteasomal degradation.染色质重塑因子 BAF155 保护乙型肝炎病毒 X 蛋白 (HBx) 免受泛素非依赖性蛋白酶体降解。
Emerg Microbes Infect. 2019;8(1):1393-1405. doi: 10.1080/22221751.2019.1666661.
6
The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A.SWI/SNF 复合物的遗传改变谱:BRD9 和 ACTL6A 的致癌作用。
PLoS One. 2019 Sep 10;14(9):e0222305. doi: 10.1371/journal.pone.0222305. eCollection 2019.
7
ARID1A promotes genomic stability through protecting telomere cohesion.ARID1A 通过保护端粒黏合促进基因组稳定性。
Nat Commun. 2019 Sep 6;10(1):4067. doi: 10.1038/s41467-019-12037-4.
8
The ATPase BRG1/SMARCA4 is a protein interaction platform that recruits BAF subunits and the transcriptional repressor REST/NRSF in neural progenitor cells.ATP 酶 BRG1/SMARCA4 是一种蛋白质相互作用平台,可招募神经祖细胞中的 BAF 亚基和转录抑制因子 REST/NRSF。
Mol Cell Biochem. 2019 Nov;461(1-2):171-182. doi: 10.1007/s11010-019-03600-0. Epub 2019 Aug 20.
9
SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.SMARCA2 缺陷使食管鳞状细胞癌细胞系对 SMARCA4 的靶向抑制敏感。
Sci Rep. 2019 Aug 12;9(1):11661. doi: 10.1038/s41598-019-48152-x.
10
Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.免疫细胞化学法检测 ARID1A 作为膀胱癌尿细胞学潜在的生物标志物。
Cancer Cytopathol. 2019 Sep;127(9):578-585. doi: 10.1002/cncy.22167. Epub 2019 Aug 6.